Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT387 in Myelofibrosis
NCT00935987Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2009
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of momelotinib dihydrochloride in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by GSK. Started Nov 2009; status: completed.
02
Drugs
momelotinib dihydrochloride
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on NCT00935987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00935987.